700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ ReadersThis Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
|National Sun Yat-sen University, Taiwan|
|Posters & Accepted Abstracts: J Cancer Sci Ther|
|Sensitive determination of the pharmacokinetics of PEGylated molecules can accelerate the process of drug development. Here, we combined different anti-PEG Fab expressing 293T cells as capture cells (293T/3.3, 293T/6.3, and 293T/15-2b cells) with four detective anti-PEG antibodies (3.3, 6.3, 7A4, or 15-2b) to optimize an anti-PEG cell-based sandwich ELISA. Then, we quantified free PEG (mPEG2K-NH2 and mPEG5K-NH2) or PEG-conjugated small molecules (mPEG5K-biotin and mPEG5K-NIR797), proteins (PegIntron and Pegasys), and nanoparticles (Liposomal-Doxorubicin and quantum-dots). The combination of 293T/15-2b cells and the 7A4 detection antibody showed best sensitivity for free PEG, PEG-like molecules, and PEGylated proteins with detection at ng mL−1 levels. On the other hand, 293T/3.3 cells combined with the 15-2b antibody had the highest sensitivity for quantifying Lipo-Dox at 2 ng mL−1. All three types of anti-PEG cells combined with the 15-2b antibody had high sensitivity for quantum dot quantification down to 7 pM. These results suggest that the combination of 293T/15-2b cells and 7A4 detection antibody is the optimal pair for sensitive quantification of free PEG, PEG-like molecules, and PEGylated proteins, whereas the 293T/3.3 cells combined with 15- 2b are more suitable for quantifying PEGylated nanoparticles. The optimized anti-PEG cell-based sandwich ELISA can provide a sensitive, precise, and convenient tool for the quantification of a range of PEGylated molecules.|
Wen-Wei Lin received BS degree in 2009 from Kaohsiung Medical University, Taiwan, with a major in Biomedical Science and Environmental Biology. He received MSc degree in 2011 from the Graduate Institute of Oral Biology at National Taiwan University. He is currently a PhD student at the Institute of Biomedical Sciences in National Sun Yat-sen University, working in the laboratory of Prof. Tian-Lu Cheng for development of antibody drugs. His research interest is antibody engineering, targeted therapy of cancer and drug discovery.
Email: [email protected]
|PDF | HTML|